Eltrombopag in thrombocytopenia.
Lawson
Adam
A
D001565:Benzoates / Q000494:pharmacology / Q000627:therapeutic use*; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D007372:Interferons / Q000009:adverse effects; D008103:Liver Cirrhosis / Q000097:blood*; D010976:Platelet Count; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011720:Pyrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D053628:Receptors, Thrombopoietin / Q000819:agonists*; D011994:Recombinant Proteins; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*
D001565:Benzoates; D006834:Hydrazines; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011720:Pyrazoles; D053628:Receptors, Thrombopoietin; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D007372:Interferons; C100416:peginterferon alfa-2a; C520809:eltrombopag